Nature Reviews Drug Discovery
@natrevdrugdiscov.nature.com
📤 4894
📥 54
📝 252
Editorial team of Nature Reviews Drug Discovery www.nature.com/nrd
Analysis of phase II and phase III clinical trial terminations from 2013 to 2023
www.nature.com/articles/d41...
This new article analyses trials terminated before completion by sponsors, highlighting strategy/business reasons as a driver of an overall increase in annual terminations
7 days ago
0
4
0
Trends in target novelty in oncology R&D
nature.com/articles/d41...
This new article analyses the novelty of targets being investigated in oncology drug R&D, and reveals that the majority of late-stage oncology drugs do not have a novel target
loading . . .
Trends in target novelty in oncology R&D
Discover the world’s best science and medicine | Nature.com
https://nature.com/articles/d41573-025-00199-4
9 days ago
0
4
1
Betting on β-catenin inhibitors in oncology
www.nature.com/articles/d41...
The WNT–β-catenin pathway is often overactive in cancer. Can emerging drugs — including stabilized peptides, condensate modulators and degraders — safely and effectively tamp it back down?
loading . . .
Betting on β-catenin inhibitors in oncology
The WNT–β-catenin pathway is often overactive in cancer. Can emerging drugs — including stabilized peptides, condensate modulators and degraders — safely and effectively tamp it back down?
https://www.nature.com/articles/d41573-025-00206-8
10 days ago
0
3
1
How multispecific molecules are transforming pharmacotherapy
rdcu.be/eUp4U
nature.com/articles/s41...
This article in the December issue discusses how drugs designed to engage two or more entities are overcoming development barriers such as toxicity and redundancy
14 days ago
0
3
0
For readers interested in GLP-1-based therapies for metabolic diseases and beyond, here's a recent review
rdcu.be/eT39F
nature.com/articles/s41...
loading . . .
GLP-1-based therapies for diabetes, obesity and beyond
Nature Reviews Drug Discovery - GLP-1-based therapies represent highly effective treatments for patients with type 2 diabetes and obesity. This Review profiles established and emerging GLP-1-based...
https://rdcu.be/eT39F
16 days ago
0
5
0
Top product forecasts for 2026
nature.com/articles/d41...
The top ten best-selling drugs are projected to generate sales of US$198 billion in 2026, driven by the GLP-1-based products for metabolic diseases. Find out more in this new article.
16 days ago
0
1
0
For readers interested in genome editing therapeutics, this Review in the December issue discusses progress in the application of CRISPR-based genome editing to treat inherited blood disorders such as sickle cell disease
rdcu.be/eTR9i
www.nature.com/articles/s41...
loading . . .
CRISPR-based therapeutic genome editing for inherited blood disorders
Nature Reviews Drug Discovery - CRISPR-based technologies provide a diverse set of tools to correct pathogenic mutations. This Review describes the promise and the challenges of genome editing...
https://rdcu.be/eTR9i
17 days ago
0
2
0
For readers interested in drugs targeting TNF superfamily members such as APRIL and their receptors, here's a comprehensive review
rdcu.be/eTG0e
www.nature.com/articles/s41...
loading . . .
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer
Nature Reviews Drug Discovery - Members of the TNF superfamily (TNFSF) of ligands and their receptors have emerged as promising targets in the treatment of autoimmune diseases and cancer, with...
https://rdcu.be/eTG0e
18 days ago
0
1
0
First-in-class APRIL inhibitor secures approval for rare kidney disease
www.nature.com/articles/d41...
18 days ago
0
0
0
For readers interested in drug repurposing, this article overviews computational approaches to drug repurposing and evaluates available in silico resources
rdcu.be/eSY57
www.nature.com/articles/s41...
23 days ago
0
5
3
Stimulating medicines repurposing in the EU: a pilot project
nature.com/articles/d41...
This new article discusses a project testing a framework to support not-for-profit organizations and academia to generate the evidence needed for a regulatory submission of a repurposed drug
loading . . .
Stimulating medicines repurposing in the EU: a pilot project
Discover the world’s best science and medicine | Nature.com
https://nature.com/articles/d41573-025-00198-5
23 days ago
0
2
2
The FDA recently approved the 100th small-molecule kinase inhibitor, a quarter of a century on from the landmark approval of imatinib. Read about progress and the key trends in the field in this article in the December issue
www.nature.com/articles/d41...
24 days ago
0
2
0
Our December issue is live! Read about how multispecific molecules are transforming pharmacotherapy, CRISPR-based genome editing for blood disorders, advances in the treatment of lupus, progress with small-molecule kinase inhibitors and more here
www.nature.com/nrd/volumes/...
24 days ago
0
3
0
Chemical modifications can improve the stability, efficiency and specificity of RNA therapeutics, while reducing their immunogenicity - find out more in this review
rdcu.be/eSyD6
www.nature.com/articles/s41...
25 days ago
0
1
0
reposted by
Nature Reviews Drug Discovery
Shinya Tsukiji
about 1 month ago
Excellent review on induced proximity-based therapeutic modalities! Thank you,
@dannomura.bsky.social
, for featuring our work in the "Targeted Protein Subcellular Localization" section and in Fig. 8!
add a skeleton here at some point
0
2
1
reposted by
Nature Reviews Drug Discovery
Fiona H Marshall
about 1 month ago
Happy to share this landscape analysis from Novartis
#GlobalHealth
colleagues published in
@natrevdrugdiscov.nature.com
exploring 2 decades of data on approvals, clinical dev. trends, and modalities across 40 diseases with major GH implications.
www.nature.com/articles/d41...
loading . . .
Innovation in medicines for global health: a 20-year landscape analysis
Discover the world’s best science and medicine | Nature.com
https://www.nature.com/articles/d41573-025-00164-1
0
4
1
For readers interested in drug development for malaria, here's a review covering strategies to combat drug resistance in malaria, HIV and tuberculosis
rdcu.be/eRVfv
www.nature.com/articles/s41...
30 days ago
0
4
1
Novel antimalarial passes key phase III test
www.nature.com/articles/d41...
Novartis’s ganaplacide plus lumefantrine (GanLum) is as effective as standard-of-care artemether plus lumefantrine (Coartem) for acute, uncomplicated malaria due to P. falciparum
30 days ago
0
2
1
Epigenetic editing: from concept to clinic
rdcu.be/eRJBO
www.nature.com/articles/s41...
Epigenetic editing aims to reprogramme gene expression by rewriting epigenetic signatures, without editing of the genome. Find out about progress in the field in this new Review
about 1 month ago
0
2
0
Advancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action
www.nature.com/articles/d41...
This new Comment article presents recommendations to address barriers to the implementation of pharmacogenomics
about 1 month ago
0
1
0
For readers interested in the frontiers of cell therapies for cancer, here's a review on in vivo CAR-T cells, which could address some of the limitations of the approved ex vivo therapies
rdcu.be/eQ9Ho
www.nature.com/articles/s41...
loading . . .
In vivo chimeric antigen receptor (CAR)-T cell therapy
Nature Reviews Drug Discovery - In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo...
https://rdcu.be/eQ9Ho
about 1 month ago
0
3
0
Accelerating progress in immune cell therapy for solid tumours
www.nature.com/articles/d41...
This Comment article discusses how collaborative translational research and adaptive clinical trial design are needed to advance novel T cell therapies towards achieving cures in solid tumours
about 1 month ago
0
2
0
Targeting the Hippo pathway in cancer
rdcu.be/eQL6l
nature.com/articles/s41...
This Review in the November issue discusses Hippo pathway-targeted therapies, particularly those that target TEAD proteins and their interaction with the YAP/TAZ transcription co-activators
about 1 month ago
0
1
0
For readers interested in therapeutic strategies based on inducing proximity between proteins, such as Halda's RIPTACs, here's a review on the field
www.nature.com/articles/s41...
rdcu.be/eQzXF
and a news story on RIPTACs
www.nature.com/articles/d41...
loading . . .
Induced proximity-based therapeutic modalities - Nature Reviews Drug Discovery
Induced proximity modalities encompass monovalent and bifunctional agents, such as molecular glues and proteolysis-targeting chimeras, that induce an interaction between biomolecules to functionally m...
https://www.nature.com/articles/s41573-025-01316-z
about 1 month ago
0
7
5
reposted by
Nature Reviews Drug Discovery
STAT
about 1 month ago
Johnson & Johnson said Monday it will purchase Halda Therapeutics and its experimental prostate cancer drugs for $3.05 billion.
www.statnews.com/2025/11/17/h...
loading . . .
Johnson & Johnson acquires Halda Therapeutics for $3 billion, a big win for a buzzy new technology
Johnson & Johnson said it will purchase Halda Therapeutics, marking the first major buyout for a cancer drugmaker built around so-called PROTACs, a buzzy new technology.
https://www.statnews.com/2025/11/17/halda-therapeutics-protacs-cancer-drugs-jnj/
1
5
4
FDA approves 100th small-molecule kinase inhibitor
www.nature.com/articles/d41...
From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
about 1 month ago
0
7
2
For readers interested in GLP-1-based therapies for diabetes, obesity and beyond, here's a recent review
rdcu.be/ePXoK
www.nature.com/articles/s41...
loading . . .
GLP-1-based therapies for diabetes, obesity and beyond
Nature Reviews Drug Discovery - GLP-1-based therapies represent highly effective treatments for patients with type 2 diabetes and obesity. This Review profiles established and emerging GLP-1-based...
https://rdcu.be/ePXoK
about 1 month ago
0
2
1
Lilly’s tirzepatide and Novo Nordisk’s semaglutide vie for top drug spot
nature.com/articles/d41...
The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab
about 1 month ago
0
1
0
reposted by
Nature Reviews Drug Discovery
Daniel Drucker
about 1 month ago
New from the
@hansclevers.bsky.social
group Drug screening and human organoids
@natrevdrugdiscov.nature.com
www.nature.com/articles/s41...
loading . . .
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges - Nature Reviews Drug Discovery
Human organoids provide physiologically relevant, 3D models for studying disease mechanisms, drug efficacy and toxicity. This Review examines organoid generation methods, applications in preclinical d...
https://www.nature.com/articles/s41573-025-01317-y
0
2
1
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
www.nature.com/articles/s41...
rdcu.be/ePz9n
This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges
loading . . .
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges - Nature Reviews Drug Discovery
Human organoids provide physiologically relevant, 3D models for studying disease mechanisms, drug efficacy and toxicity. This Review examines organoid generation methods, applications in preclinical d...
https://www.nature.com/articles/s41573-025-01317-y
about 1 month ago
0
3
1
This article in the November issue discusses the changing landscape of medicinal chemistry optimization based on analysis of sets of hits, leads and drug candidates, which reveals shifts in key physicochemical properties
rdcu.be/ePoB9
www.nature.com/articles/s41...
loading . . .
The changing landscape of medicinal chemistry optimization
Nature Reviews Drug Discovery - Medicinal chemistry optimizations in the progression from hit to lead to drug candidate affect properties of small-molecule drugs such as their molecular weight and...
https://rdcu.be/ePoB9
about 1 month ago
0
4
1
For readers interested in therapies that harness regulatory T cells to treat disease, here's a review on this topic
rdcu.be/ePb76
www.nature.com/articles/s41...
and a review discussing their potential to reset the immune system
rdcu.be/ePb8b
www.nature.com/articles/s41...
loading . . .
Harnessing the biology of regulatory T cells to treat disease
Nature Reviews Drug Discovery - Regulatory T cells keep the immune system in check to maintain homeostasis and restrain inflammation. This Review discusses strategies to harness these cells...
https://rdcu.be/ePb76
about 2 months ago
0
2
0
“It’s about time”: Tregs win the Nobel prize
www.nature.com/articles/d41...
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview
loading . . .
“It’s about time”: Tregs win the Nobel prize
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of Treg therapies.
https://www.nature.com/articles/d41573-025-00186-9
about 2 months ago
0
2
1
For readers interested in bispecific antibodies as cancer therapies, here's a review
rdcu.be/eOONr
www.nature.com/articles/s41...
loading . . .
The present and future of bispecific antibodies for cancer therapy
Nature Reviews Drug Discovery - Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent...
https://rdcu.be/eOONr
about 2 months ago
0
0
1
Innovative antibody therapeutic development in China compared with the USA and Europe
nature.com/articles/d41...
Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
loading . . .
Innovative antibody therapeutic development in China compared with the USA and Europe
Discover the world’s best science and medicine | Nature.com
https://nature.com/articles/d41573-025-00185-w
about 2 months ago
0
0
0
Cancer cell therapies: global clinical trial trends and emerging directions
www.nature.com/articles/d41...
This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
loading . . .
Cancer cell therapies: global clinical trial trends and emerging directions
Discover the world’s best science and medicine | Nature.com
https://www.nature.com/articles/d41573-025-00180-1
about 2 months ago
0
0
0
For readers interested in the development of drugs for fibrotic diseases such as idiopathic pulmonary fibrosis, here's a review discussing the underlying biology and how to address the translational research challenges
rdcu.be/eOpGH
www.nature.com/articles/s41...
loading . . .
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Nature Reviews Drug Discovery - Fibrosis is a key characteristic of a range of chronic diseases that has been challenging to target with drugs. This Review highlights core pathways active in...
https://rdcu.be/eOpGH
about 2 months ago
0
5
2
FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis
www.nature.com/articles/d41...
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
about 2 months ago
0
2
0
Induced proximity-based therapeutic modalities
nature.com/articles/s41...
rdcu.be/eOfBH
This new Review by
@dannomura.bsky.social
et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
loading . . .
Induced proximity-based therapeutic modalities - Nature Reviews Drug Discovery
Induced proximity modalities encompass monovalent and bifunctional agents, such as molecular glues and proteolysis-targeting chimeras, that induce an interaction between biomolecules to functionally m...
https://nature.com/articles/s41573-025-01316-z
about 2 months ago
0
21
10
For readers interested in new drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review
rdcu.be/eN4SK
www.nature.com/articles/s41...
about 2 months ago
1
1
0
reposted by
Nature Reviews Drug Discovery
FirstWord Group
about 2 months ago
Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY
firstwordpharma.com/story/6511061
0
0
1
Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here
www.nature.com/nrd/volumes/...
about 2 months ago
0
5
2
For readers interested in new drugs for chronic obstructive pulmonary disease, here's a comprehensive review
rdcu.be/eNiYv
www.nature.com/articles/s41...
loading . . .
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
Nature Reviews Drug Discovery - Chronic obstructive pulmonary disease (COPD) is a progressive and severe respiratory disease featuring airway obstruction and recurrent exacerbations, driven by a...
https://rdcu.be/eNiYv
about 2 months ago
0
3
0
reposted by
Nature Reviews Drug Discovery
pharmaphorum
about 2 months ago
In its second pipeline-expanding deal in the space of 24 hours,
#GSK
has licensed rights to a drug for chronic obstructive pulmonary disease (#COPD) from US biotech
#Empirico
for $85 million upfront.
pharmaphorum.com/news/gsk-str...
0
1
1
For readers interested in the potential to target particular protein isoforms as a way to achieve greater drug specificity, here's a review
rdcu.be/eNiHj
www.nature.com/articles/s41...
loading . . .
Protein isoform-centric therapeutics: expanding targets and increasing specificity
Nature Reviews Drug Discovery - Multiple protein isoforms arise from most genes by alternative RNA splicing and other mechanisms, but these isoforms are often neglected in drug discovery. This...
https://rdcu.be/eNiHj
about 2 months ago
0
2
1
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety
www.nature.com/articles/s41...
rdcu.be/eM8hs
This new Perspective discusses QST models for multiple organs and provides recommendations for building and applying them
loading . . .
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety - Nature Reviews Drug Discovery
Quantitative systems toxicology (QST) models have the potential to increase confidence in the safety assessment of drug candidates and to inform project progression decisions. This article overviews t...
https://www.nature.com/articles/s41573-025-01308-z
about 2 months ago
0
1
0
For readers interested in lipid nanoparticles for nucleic acid delivery, here's a perspective by Cullis and Feldner on the evolution of the field
rdcu.be/eMpeO
nature.com/articles/s41...
loading . . .
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Nature Reviews Drug Discovery - Lipid nanoparticle-based systems are increasingly being utilized for the delivery of nucleic acid-based vaccines and therapeutics. In this Perspective, Cullis and...
https://rdcu.be/eMpeO
2 months ago
0
6
1
Trends in gene therapy delivery technologies
nature.com/articles/d41...
This article analyses trends in the delivery vehicles used for gene therapies in the clinical pipeline and discusses the potential characteristics of best-in-class delivery
loading . . .
Trends in gene therapy delivery technologies
Discover the world’s best science and medicine | Nature.com
https://nature.com/articles/d41573-025-00171-2
2 months ago
0
2
0
reposted by
Nature Reviews Drug Discovery
Nature Portfolio
2 months ago
Join researchers, biotech innovators, and pharma leaders in Boston this December for Cracking the Code: Nucleic Acid Medicines Coming of Age. Explore how advances in RNA and DNA therapeutics are shaping the next generation of medicine.
go.nature.com/4nbCcaK
🧬
#STEMconference
0
6
3
Intrinsically disordered proteins are frequently dysregulated in disease, but have traditionally been considered 'undruggable'. This Review in the October issue discusses experimental and computational approaches to conquer this barrier in drug discovery
rdcu.be/eMbXh
www.nature.com/articles/s41...
loading . . .
Targeting protein disorder: the next hurdle in drug discovery
Nature Reviews Drug Discovery - Intrinsically disordered proteins are frequently dysregulated in many diseases, but because of their heterogeneous, highly dynamic structural states they have been...
https://rdcu.be/eMbXh
2 months ago
0
6
1
Load more
feeds!
log in